Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes.
- Author:
Feng DU
1
;
Peng YUAN
1
;
Yang LUO
1
;
Jiayu WANG
1
;
Fei MA
1
;
Ruigang CAI
1
;
Ying FAN
1
;
Qing LI
1
;
Pin ZHANG
1
;
Binghe XU
2
;
Email: XUBINGHE@MEDMAIL.COM.CN.
Author Information
- Publication Type:Journal Article
- MeSH: Anthracyclines; therapeutic use; Antibiotics, Antineoplastic; adverse effects; therapeutic use; Antineoplastic Agents, Phytogenic; adverse effects; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Bridged-Ring Compounds; therapeutic use; Capecitabine; administration & dosage; Cisplatin; administration & dosage; Disease-Free Survival; Humans; Neutropenia; chemically induced; Retrospective Studies; Taxoids; therapeutic use; Triple Negative Breast Neoplasms; drug therapy; pathology; Vinblastine; adverse effects; analogs & derivatives; therapeutic use
- From: Chinese Journal of Oncology 2015;37(10):788-792
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo assess the efficacy of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes.
METHODSClinical data of 48 patients diagnosed and treated for mTNBC between 2004 and 2012 at the Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) were retrospectively analyzed. All patients were pretreated with anthracyclines and at least one taxane in neo-adjuvant, adjuvant or chemotherapy for mTNBC and patients should be having at least one measurable metastatic lesion. Totally, 48 patients were included in this study, of which 21 cases received first-line chemotherapy and 27 cases received second-line chemotherapy. Based on the regimen they received, 22 patients were treated with NVB plus platinum (NP), and 26 patients with NVB plus capecitabine (NX).
RESULTSAfter 70 months follow-up, in the total group of patients, the objective response rate was 20.8%, clinical benefit rate was 43.8%, median progression free survival (PFS) was 4.4 months and median overall survival (OS) was 15.5 months. In addition, the ORR was significantly better in the NP arm versus NX arm (33.8% vs.7.7%, P=0.029) as well as PFS was statistically improved in the NP arm than NX arm (5.3 m vs. 3.0 m, P=0.023). Similar trend was observed in the OS, although the difference was not statistically significant (27.7 m vs. 14.8 m, P=0.077). In all, the most frequently reported adverse events were G1/2 gastrointestinal toxicity (68.8%) and neutropenia (62.5%) . No significant difference was observed between the NP arm and NX arm (P>0.05). The percentage of patients who delayed chemotherapy administration in the NP arm and NX arm was 9.1% (n=2), and 3.8% (n=1), respectively.
CONCLUSIONSNVB-based combination chemotherapy demonstrates moderate efficacy in mTNBC patients pretreated with anthracyclines and one taxane with manageable toxicity. NP regimen shows potential superiority over NX regimen, and should be further verified in randomized phase III clinical trial in larger cohort.
